{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He X"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","University of Cincinnati","Ohio Lions Eye Research Foundation"],"pagination":["1461-1469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11971978"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(2)"],"pubmed_abstract":["To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may lead to local side effects. The present study attempts to develop a dosage-controllable drug delivery implant that consists of a nanoporous biodegradable PLGA capsule and light-activated liposomes. Controllable drug release from the implant was achieved using a pulsed near-infrared (NIR) laser both in vitro and in vivo. The in vitro drug release kinetics from two different initial dose implants, 1000 and 500 μg, was analyzed by fitting zero-order and first-order kinetics, as well as the Korsmeye"],"journal":["ACS applied bio materials"],"pubmed_title":["Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye."],"pmcid":["PMC11971978"],"funding_grant_id":["5KL2TR001426-04","KL2 TR001426"],"pubmed_authors":["Park YC","Kao WW","Li SK","He X","Miller D","Gaeke S","Yuan Z","Williams B"],"additional_accession":[]},"is_claimable":false,"name":"Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye.","description":"To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may lead to local side effects. The present study attempts to develop a dosage-controllable drug delivery implant that consists of a nanoporous biodegradable PLGA capsule and light-activated liposomes. Controllable drug release from the implant was achieved using a pulsed near-infrared (NIR) laser both in vitro and in vivo. The in vitro drug release kinetics from two different initial dose implants, 1000 and 500 μg, was analyzed by fitting zero-order and first-order kinetics, as well as the Korsmeye","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2025-07-08T03:13:46.622Z","creation":"2025-07-08T03:13:46.622Z"},"accession":"S-EPMC11971978","cross_references":{"pubmed":["35014495"],"doi":["10.1021/acsabm.0c01334"]}}